The latest victory in a years-long hepatitis C patent battle between Gilead Sciences and Merck goes to Gilead. On Friday, a federal judge overturned a $2.54 billion verdict against the biotech on grounds that a key Merck patent used to support the infringement lawsuit is invalid.Original Article
Gilead wins reversal of $2.54B hepatitis C patent verdict, but Merck says fight not over yet
